DNDN

Recent Articles

Dendreon Bankruptcy: DNDN Files for Chapter 11

Dendreon, a biotech company that created the prostate-cancer drug Provenge, has filed for Chapter 11 bankruptcy protection. More 

DNDN: Dendreon Surges Double Digits Following Prostate Drug News

DNDN stock is up over 15% Monday following Dendreon's announcement that it will sell its prostate cancer vaccine Provenge in Europe. More 

Dendreon Earnings Suck, But Still Send DNDN Stock Higher

Dendreon shareholders don't have any more to worry about after Q3's numbers were posted, but they don't have any less to worry about with their DNDN trade either. More 

Stocks Get Another Fed Jolt: Tuesday’s IP Market Recap

Wall Street got a little oomph from Atlanta Federal Reserve chief comments indicating that September tapering wasn't a foregone conclusion. More 

Dendreon Looks Like a Buy After Meltdown

The Dendreon rags-to-riches-to-rags story saga has a light at the end of the tunnel, but can also teach investors a few valuable big-picture lessons. More 

Slow Your Roll, Wall Street: Monday’s IP Market Recap

A positive reading in U.S. manufacturing wasn't enough to help out the broader markets, though Tyson and Facebook were among some individual standouts. More 

Changing U.S. Demographics Mean a Decades-Long Healthcare Boom

The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs. More